{
    "clinical_study": {
        "@rank": "127644", 
        "arm_group": [
            {
                "arm_group_label": "Ritonavir-boosted Atazanavir", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Ritonavir-boosted Atazanavir plus Rabeprazole", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine HCl", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of this study is to evaluate the ability of a natural supplement (betaine\n      hydrochloride) to affect the absorption of atazanavir in healthy volunteers. The\n      investigators predict that betaine hydrochloride will increase the absorption of atazanavir\n      in volunteers pre-treated with proton-pump inhibitors (PPIs)."
        }, 
        "brief_title": "Effects of Gastric pH on the Pharmacokinetics of Atazanavir", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 18-65 years of age\n\n          -  Healthy adult with no active medical problems or significant chronic diseases as\n             determined by the study doctor based on history, physical exam and laboratory\n             evaluations\n\n          -  BMI between 18.5-30 kg/m2\n\n          -  Taking no medications 2 weeks before and during the study enrollment, including drugs\n             of abuse, prescription or over-the-counter (OTC) medications (except acetaminophen)\n\n          -  Subjects able to maintain adequate birth control during the study independent of\n             hormonal contraceptive use\n\n          -  Be able to provide written informed consent and comply with requirements of the study\n\n          -  Avoid eating grapefruit and drinking grapefruit juice from 7 days before the first\n             study day until the completion of the entire study\n\n          -  Abstinence from alcoholic beverages, caffeinated beverages and orange juice from 3pm\n             the night before a study day until completion of that study day\n\n          -  Fast from food and beverages at least 8 hours prior to medication dosing\n\n          -  Be able to read, speak, and understand English\n\n        Exclusion Criteria:\n\n          -  Subjects with a history of gastrointestinal disease including gastroesophageal reflux\n             disease, gastritis, peptic ulcer disease, or dyspepsia\n\n          -  Subjects with a fasting gastric pH of > 4 (i.e. hypochlorhydria)\n\n          -  Subjects with a history of dysphagia, achalasia, or difficulty swallowing capsules,\n             tablets, or pills\n\n          -  Subjects on prescription or chronic over-the-counter (OTC) medications (including\n             hormonal contraceptives)\n\n          -  Subjects with known allergies rabeprazole, any other proton pump inhibitors (PPI's)\n             or betaine hydrochloride\n\n          -  Subjects who smoke tobacco\n\n          -  Subjects with ongoing alcohol or illegal drug use\n\n          -  Subjects who are pregnant, lactating, or attempting to conceive\n\n          -  Subjects unable to maintain adequate birth control during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01759875", 
            "org_study_id": "CRS6537"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ritonavir-boosted Atazanavir", 
                "description": "Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1", 
                "intervention_name": "Ritonavir-boosted Atazanavir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ritonavir-boosted Atazanavir plus Rabeprazole", 
                "description": "Rabeprazole (20mg) PO twice daily (Days 1-3); Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 (Day 4)", 
                "intervention_name": "Ritonavir-boosted Atazanavir plus Rabeprazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine HCl", 
                "description": "Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 on Day 4", 
                "intervention_name": "Ritonavir-boosted Atazanavir plus Rabeprazole  AND Betaine Hydrochloride", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Rabeprazole", 
                "Betaine", 
                "Ritonavir", 
                "Atazanavir"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94143"
                }, 
                "name": "Clinical Research Center, UCSF"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effects of Gastric pH on the Pharmacokinetics of Atazanavir in Healthy Volunteers", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The primary outcome measure will be atazanavir area-under-the-concentration curve (AUC) values from zero-to-twenty two (0-22) hours. Values from Experimental Arms of the study (Ritonavir-boosted Atazanavir plus Rabeprazole; Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride) will be compared against the active comparator (Ritonavir-boosted atazanavir alone) and tested for statistical significance.", 
                "measure": "Area-Under-the Concentration Curve from zero-to-twenty two hours (AUC,0-22) of Atazanavir", 
                "safety_issue": "No", 
                "time_frame": "Day 4"
            }, 
            {
                "description": "The primary outcome measure will be atazanavir area-under-the-concentration curve (AUC) values from zero-to-infinite time (0-inf). Values from Experimental Arms of the study (Ritonavir-boosted Atazanavir plus Rabeprazole; Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride) will be compared against the active comparator (Ritonavir-boosted Atazanavir alone) and tested for statistical significance.", 
                "measure": "Area-Under-the Concentration Curve from zero-to-infinity (AUC,0-inf) of Atazanavir", 
                "safety_issue": "No", 
                "time_frame": "Day 4"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01759875"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Francisco", 
            "investigator_full_name": "Leslie Benet", 
            "investigator_title": "Professor, Bioengineering and Therapeutic Science", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The maximum plasma concentration (Cmax) will also be measured. Values from Experimental Arms of the study (Ritonavir-boosted Atazanavir plus Rabeprazole; Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride) will be compared against the active comparator (Ritonavir-boosted Atazanavir alone) and tested for statistical significance.", 
            "measure": "Maximum Concentration of Atazanavir", 
            "safety_issue": "No", 
            "time_frame": "Day 4"
        }, 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}